비알콜성 지방간을 가진 제2형 당뇨병 환자에서 지방간 개선에 대한 Dapagliflozin의 효과

Abstract

Background : The global prevalence of type 2 diabetes mellitus (T2DM) is rapidly growing worldwide, and accordingly, the number of patients with concomitant diseases is increasing. Type 2 diabetes mellitus is closely related to nonalcoholic fatty liver disease (NAFLD), and in this study, a meta-analysis was conducted to investigate the effect of dapagliflozin on improving liver enzyme levels in NAFLD patients taking. Methods : This study identified eligible trials based on MeSH terms in the PubMed, EMBASE, and CENTRAL database published from 2012 to March 2020 that reported effects on liver outcomes in patients with type 2 diabetes. The primary outcomes were alanine aminotransferase (ALT), aspartate aminotransferase (AST), and fibrosis-4 (FIB-4) index scores and the second outcomes were body mass index (BMI), and high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol levels. For the statistical analysis, standardized mean difference (SMD) was calculated at 95% confidence intervals (CIs), and fixed or random-effects models were used to assess the outcomes.